Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

News Daily News

FDA Clears SAPIEN 3 With Alterra Prestent for Pulmonary Valve Replacement

L.A. McKeown

December 20, 2021

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Shelley Wood

September 20, 2021

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

FDA Clears Next-Generation Sapien 3 Ultra TAVR Valve

Todd Neale

January 02, 2019

News Daily News

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Caitlin E. Cox

September 05, 2018

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

Advertisement

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

FDA Clears SAPIEN 3 With Alterra Prestent for Pulmonary Valve Replacement

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Sapien 3 Valve Approved in Europe for Low-Risk Patients

FDA Expands TAVR Indication to Low-Risk Patients

TCTMD’s Top 10 Most Popular Stories for January 2019

FDA Clears Next-Generation Sapien 3 Ultra TAVR Valve

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content